Correction to: Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials. . Eur J Heart Fail 2026 Aug 31:xuag248. doi: 10.1093.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

. Correction to: Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials. Eur J Heart Fail 2026 Aug 31:xuag248. doi: 10.1093.
PMID: 42671896